Earlier quoted context omitted.
As I stated in the sibling comment, Stemcentrx is indeed much more reasonable than either Theranos or Nootrobox. However, a $5B valuation is still absurdly optimistic when you consider the comps. There have been massive setbacks at Verastem even after getting to phase 2[0], and Verastem's science originated from a top MIT research lab. 0: https://www.bostonglobe.com/business/2015/09/28/verastem-sha...
Agreed, that is a lot if true, the MIT article[0] gave a 3 billion number and also mentions that the latest valuation was determined by Fidelity not some silicon valley VC firm. This all leads me to stick with the assertion that I would not lump the three in any way. 0: http://www.technologyreview.com/news/541006/peter-thiel-back...
You're right that Stemcentrx, unlike Theranos or Nootrobox, doesn't smell of SV hucksterism. However, rather than comparing Stemcentrx to Theranos or Nootrobox, compare them to OncoMed, Verastem, and Stemline, which have current public valuations of $700M, $65M, and $116M, respectively. And none of them ever exceeded $1.2B in their public valuations.
0: http://blogs.wsj.com/venturecapital/2015/09/16/peter-thiel-b...
1: https://www.crunchbase.com/funding-round/7db717567346f07e604...
2: http://fortune.com/2015/11/11/snapchat-isnt-the-only-startup...
3: http://fortune.com/2015/11/12/fidelity-marks-down-tech-unico...